RESUMEN
High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D ± RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA Asunto(s)
Antivirales/administración & dosificación
, Genotipo
, Hepacivirus/clasificación
, Hepatitis C Crónica/tratamiento farmacológico
, Hepatitis C Crónica/virología
, Respuesta Virológica Sostenida
, Adolescente
, Adulto
, Anciano
, Anilidas
, Carbamatos
, Ensayos Clínicos Fase III como Asunto
, Femenino
, Hepacivirus/genética
, Hepacivirus/aislamiento & purificación
, Humanos
, Masculino
, Persona de Mediana Edad
, Prolina
, ARN Viral/sangre
, Factores de Tiempo
, Resultado del Tratamiento
, Valina
, Adulto Joven
RESUMEN
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
Asunto(s)
Hepatitis C Crónica/epidemiología , Antivirales/uso terapéutico , Salud Global , Hepatitis C Crónica/mortalidad , Hepatitis C Crónica/terapia , Humanos , Incidencia , Trasplante de Hígado , Prevalencia , Análisis de SupervivenciaRESUMEN
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Pruebas Diagnósticas de Rutina/estadística & datos numéricos , Erradicación de la Enfermedad , Quimioterapia Combinada/métodos , Femenino , Salud Global , Hepatitis C Crónica/diagnóstico , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Prevalencia , Adulto JovenRESUMEN
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Quimioterapia Combinada/métodos , Femenino , Salud Global , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Prevalencia , Adulto JovenRESUMEN
OBJECTIVE: To assess the efficacy of lamivudine treatment on hepatitis B e antigen (HBeAg) and/or hepatitis B surface antigen (HBsAg) seroconversion, on other virological and serological markers of response including hepatitis B virus (HBV) DNA and serum aminotransferases, and the safety of lamivudine treatment in hepatitis B patients. PATIENTS: This phase III open-label study evaluated the virological and biochemical response to lamivudine in 70 Portuguese patients with HBeAg positive chronic hepatitis B. Patients were treated with lamivudine 100mg once daily for 12 months. METHODS: Antiviral activity was assessed by measuring alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels at all protocol visits, and hepatitis B serology and HBV DNA were performed at baseline and at month 12 visits. Evaluation of safety and tolerance was based on clinical adverse events and laboratory analyses. RESULTS: The primary endpoint was virological response at month 12, defined as loss of detectable HBeAg from serum with a reduction of HBV DNA to undetectable levels, and this was observed in 19/69 (27.5%) of patients. Almost half of the patients were HBV DNA negative by this time. Mean ALT values decreased steadily during treatment and by 12 months 61% of patients had values within the normal range. HBeAg seroconversion (HBeAg negative, HBeAb positive) was achieved in 27.9% of patients by 12 months, although all patients remained HBsAg positive. CONCLUSION: Lamivudine was well tolerated and the incidence of adverse events was similar to those reported in previous studies. Lamivudine treatment resulted in virological and biochemical improvements in HBeAg positive chronic hepatitis B patients, with HBeAg seroconversion in one-third of patients.
RESUMEN
The authors present a case report of synchronous gastric carcinoid and adenocarcinoma. The diagnosis of gastric carcinoid and its association with gastric carcinoma is discussed.
Asunto(s)
Adenocarcinoma/diagnóstico , Tumor Carcinoide/diagnóstico , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Gástricas/diagnóstico , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Tumor Carcinoide/patología , Tumor Carcinoide/cirugía , Gastrectomía , Humanos , Escisión del Ganglio Linfático , Masculino , Persona de Mediana Edad , Neoplasias Primarias Múltiples/patología , Neoplasias Primarias Múltiples/cirugía , Estómago/patología , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugíaRESUMEN
The determination of serum levels of carbohydrate deficient transferrin (CDT) and transferrin ratio in the persistent abusive alcohol consumer arises with promising utility in the study of alcohol related disorders. This series shows the excellent specificity (97%), though poor sensitivity (52%), for CDT. However the CDT/Tft ratio affords a higher sensitivity, reaching 74%, maintaining the high specificity. In persistent abusive consumers (> 70 g/day) this index, which is positively correlated with serum transferrin, is capable of defining these amounts of alcohol per capita with a high frequency and provides independent information since it is not significantly correlated with the levels of traditional biological markers (AST, ALT, GGT, AGV). Although with defined methodological limitations, these indexes denote, with the improvement of technical accessibility, a practical applicability in the screening of chronic abusive consumers. In the field of hepatology the behaviour of CDT and the transferrin ratio is capable of showing the involvement of ethanol in the study of the nature of a chronic hepatic disease with a high frequency. However, the degree of liver lesion show by the PGA hepatic index, has no significant influence on the serum levels of CDT and the transferrin ratio. In this series, the circumstances and conditions of alcohol consumption seem to be the independent determinant of the informative character which these indexes reveal.